Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

2.75 億美元集體訴訟和解惠及消費者及第三方付款機構,終端付款人原告公佈處方仿製藥案件
  • USA - español
  • USA - Chinese
  • USA - English


News provided by

Fine, Kaplan, and Black, R.P.C.

Mar 10, 2025, 15:00 ET

Share this article

Share toX

Share this article

Share toX

費城2025年3月10日 /美通社/ -- 

法律聲明 

Fine, Kaplan, and Black, R.P.C. 律師事務所公佈:若閣下
於 2009 年 5 月 1 日至 2019 年 12 月 31 日期間,在美國境內
購買、支付或報銷若干處方仿製藥的費用,閣下或有資格從集體訴訟和解中獲得賠償。

本通知已獲聯邦法院授權發佈。
本公告並非律師招攬。查詢電話:

1-877-316-0171 網址:
www.GenericDrugsEndPayerSettlement.com

Para conseguir una notificación en español, llame a 1-877-316-0171 o visite el sitio web:
www.GenericDrugsEndPayerSettlement.com

閣下之法律權利或會受一項涉及 2.75 億美元的擬議集體訴訟和解(「仿製藥反壟斷訴訟案」,案號:16-MD-2724)所影響。該訴訟現正於美國賓夕法尼亞州東區地方法院審理。訴訟指控 Sandoz Inc. 及 Fougera Pharmaceuticals Inc. (統稱「Sandoz」) 以及其他仿製藥製造商(「非和解被告」)違反聯邦及州的反壟斷法、消費者保障法規和普通法,導致終端付款人 — 包括消費者及第三方付款機構 (「TPP」)(例如:保險公司或設有自行承保處方藥物計劃的僱主等實體)— 就若干處方仿製藥(「指定仿製藥」)支付過高的費用。Sandoz 否認對終端付款人負有任何法律責任。法院尚未就訟訴雙方之理據作出裁決。針對非和解被告的訴訟仍在進行中。

本人是否為和解集體的成員?本訴訟由指定仿製藥的終端付款人 (「EPP」) 提出,而法院已初步認證 EPP Sandoz 和解集體,成員包括第三方付款機構及消費者。若閣下為第三方付款機構或消費者,並於 2009 年 5 月 1 日至 2019 年 12 月 31 日期間,在美國境內(印第安納州及俄亥俄州除外)及若干美國領土,曾間接購買、支付和/或報銷一種或多種指定仿製藥的部分或全部購買價格,以供閣下或閣下的成員作個人用途(而非轉售),則閣下可能屬於和解集體的成員。若干類別的實體並不包括在和解集體內。更詳盡的通知載有關於和解集體的完整定義,以及哪些人士屬於或不屬於和解集體成員、指定仿製藥清單、被告的完整名單,以及和解協議的詳情,可於 www.GenericDrugsEndPayerSettlement.com 查閱。

和解協議的內容為何? 根據擬議的和解協議,Sandoz 已向和解基金支付 2.75 億美元。在若干情況下,和解基金的金額或會減少,詳情請參閱和解協議。和解基金在扣除和解通知及行政管理費用(上限為 750,000 美元)後,將用於向合資格的和解集體成員支付賠償;此外,在法院批准下,亦會扣除律師費(最多為基金的三分之一另加利息)、訴訟開支(上限為 26,000,000 美元),以及向和解集體代表支付的服務酬金(總額上限為 500,000 美元)。和解集體律師將於 www.GenericDrugsEndPayerSettlement.com 公佈其就費用、開支及服務酬金的申請。Sandoz 亦同意與終端付款人合作,提供與終端付款人向非和解被告提出訴訟的相關資料。

如何獲取賠償? 若法院批准和解協議,將會進行賠償分配。賠償金額及時間將根據法院批准的分配方案而定。終端付款人提出的擬議分配方案已於 www.GenericDrugsEndPayerSettlement.com 公佈。索償程序將於稍後展開。如欲獲取有關和解的最新資訊,包括索償表格的發放時間,閣下應於 www.GenericDrugsEndPayerSettlement.com 註冊或致電 1-877-316-0171。

若本人為和解集體成員,可作何選擇?若閣下不採取任何行動,閣下將繼續成為和解集體成員,並有資格參與和解,受法院就和解及針對 Sandoz 的申索所作出的裁決之法律約束,而閣下將不能自行向 Sandoz 提出申索。若閣下不希望受和解協議的法律約束,或希望保留自行起訴 Sandoz 的權利,則必須選擇退出和解。若閣下選擇留在和解集體,但反對部分或全部的和解協議、擬議的分配方案、律師費、開支或擬議服務酬金的申請,閣下可以提出反對。有關如何申請退出和解或提出反對的詳情,請瀏覽 www.GenericDrugsEndPayerSettlement.com。任何退出和解或提出反對的要求,必須於 2025 年 5 月 9 日或之前提交。法院將於 2025 年 7 月 23 日上午 11 時正舉行公平聆訊,決定是否批准和解協議、分配方案,以及任何關於律師費、開支或服務酬金的申請。若閣下有意出席聆訊,必須向法院提交「出庭意向通知書」,閣下亦可(但非必須)自行聘請律師代表閣下出庭,費用自理。法院或會更改截止日期或聆訊日期及時間。請瀏覽 www.GenericDrugsEndPayerSettlement.com 查閱最新資訊。

Fine, Kaplan, and Black, R.P.C.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

Fine, Kaplan and Black, R.P.C. 律師事務所宣佈集體訴訟和解案,若您於 2009 年 5 月 1 日至 2019 年 12 月 31 日期間,在美國境內曾支付或報銷特定處方通用藥品費用,請注意以下事項

法律聲明 在 2009 年 5 月 1 日至 2019 年 12 月 31 日期間,如果您支付或報銷了特定處方學名藥的費用,您可以從集體訴訟和解決方案中獲得付款。 本公告經聯邦法院授權。 這並非律師的邀請。 1-877-316-0171...

Fine, Kaplan and Black, R.P.C., Announce a Class Action Settlement If You Paid or Reimbursed for Certain Prescription Generic Drugs in the United States Between May 1, 2009 and December 31, 2019

LEGAL NOTICE If You Paid or Reimbursed for Certain PRESCRIPTION GENERIC DRUGS in the United States between May 1, 2009 and December 31, 2019, You...

More Releases From This Source

Explore

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Asian American

Asian American

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.